Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / TECH - Should You Invest in UiPath Ahead of Q1 Earnings? | Benzinga


TECH - Should You Invest in UiPath Ahead of Q1 Earnings? | Benzinga

UiPath Inc. (NYSE: PATH) is set to report its first-quarter fiscal 2025 results on May 29, after the bell.

The company has an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an earnings surprise of 192% on average.

Let's check out how PATH is currently doing.

Stock Looks Cheap Upon Correction

The stock has declined 23.6% year to date against the 14% rally of the industry and the 11.5% rise of the Zacks S&P 500 composite.

UiPath, Inc. Price

UiPath, Inc. price | UiPath, Inc. Quote

On the basis of Price/Earnings, PATH is currently trading at 31.42X compared with the industry's 37.30X. If we look at the Price/Sales ratio, PATH shares currently trade at 6.57X forward sales, slightly below the industry's 6.84X.

Strong Business Model & Expense Management

The company's strong business model that ensures efficient delivery of its end-to-end automation platform services drove the 31% year-over-year revenue growth in the fourth quarter of fiscal 2024. Increases in revenues, expense management and operating discipline have positively impacted the bottom line in the quarter, driving non-GAAP operating margin by 500 basis points.

Ease of Paying Off ...

Full story available on Benzinga.com

Stock Information

Company Name: Bio-Techne Corp
Stock Symbol: TECH
Market: NASDAQ
Website: bio-techne.com

Menu

TECH TECH Quote TECH Short TECH News TECH Articles TECH Message Board
Get TECH Alerts

News, Short Squeeze, Breakout and More Instantly...